Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Mylan in
the generic pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key branded drugs. An
interactive data and analysis tool provides quantitative and qualitative
information.
Reasons to Purchase
- Understand the impact of Mylan' s acquisition of Merck KGaA' s generics
business on its corporate strategy and performance
- Benchmark Mylan' s performance against key rivals in the generic
pharmaceutical sector
- Evaluate Mylan' s historical and forecast, branded and generic growth
drivers and resistors
View Cart
